Treatment-related adverse events, immune-related adverse events and discontinuation in patients with solid tumors adding adjuvant immune checkpoint blockade: a meta-analysis of 38 randomized controlled trials

作者
Wangcheng Zhao,Zhi Yang,Quanming Fei,Xinhang Hu,Yifan Ouyang,Xuyang Yi,Shouzhi Xie,Li Wang,Xingchun Huang,Yu He,Juan Luo,Xiao Ye,Zhe Zhang,Fenglei Yu
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:111 (7): 4756-4771 被引量:5
标识
DOI:10.1097/js9.0000000000002480
摘要

BACKGROUND: The safety profile of immune checkpoint blockade (ICB) in the adjuvant setting has not been well characterized. This study aims to summarize the incidences of adverse events (AEs) in patients with solid tumors receiving ICB in adjuvant setting, and evaluate the effect of ICB addition on incidences of these adverse events. METHODS: We searched public databases and relevant international conference proceedings up to 20 September 2024, to identify eligible randomized controlled trials evaluating the ICB-based treatments in adjuvant setting for patients with solid tumors. The primary outcomes included treatment-related death, treatment-related adverse events (TrAEs), immune-related adverse events (IrAEs), serious AEs, and discontinuation due to AEs. The GRADE approach was used to evaluate the certainty of evidence for primary outcomes. RESULTS: Thirty-eight trials with 25 852 participants were included. Single-arm meta-analysis showed that combination therapies had a higher incidence of grade 3-4 TrAEs than PD-1/PD-L1 monotherapy, while anti-CTLA-4-based therapies exhibited higher discontinuation rates (49.7% [39.4-60.0] for anti-CTLA-4 monotherapy) versus other ICB strategies. Treatment-related death was rare, occurring in 63 of 16 272 participants receiving adjuvant ICB-based treatments. The pairwise meta-analysis revealed that the addition of ICB was associated with increased treatment-related deaths (OR [95% CI]: 1.713 [1.117-2.628]), although this association was observed only in the CTLA-4 blockade and not in the PD-1 or PD-L1 blockade. ICB addition also increased incidences of TrAEs, IrAEs, serious AEs, and discontinuations, with consistent results across blockade types. Additionally, ICB addition was associated with higher incidences of 37 types of AEs, including 20 grade 3-4 events. Most results had moderate evidence quality. CONCLUSION: Adding ICB in adjuvant setting was associated with increased AEs, but the toxicity profile was largely similar to that in the advanced setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LFY完成签到,获得积分10
刚刚
qi发布了新的文献求助10
1秒前
郝子凯发布了新的文献求助10
1秒前
本本完成签到,获得积分10
1秒前
yyc发布了新的文献求助10
2秒前
2秒前
2秒前
Hello的应助被Daisy采纳,获得10
3秒前
yurise发布了新的文献求助10
3秒前
兴奋石头发布了新的文献求助10
3秒前
Cataphyll完成签到,获得积分10
3秒前
4秒前
xyh发布了新的文献求助10
4秒前
4秒前
wanci的应助被村上种树采纳,获得10
5秒前
6秒前
7秒前
三叁完成签到,获得积分10
7秒前
五颜六色李云龙完成签到,获得积分10
7秒前
STARRY发布了新的文献求助10
7秒前
云雀发布了新的文献求助10
7秒前
余香的应助被周末采纳,获得10
7秒前
8秒前
研友_VZG7GZ的应助被沉静妙之采纳,获得10
8秒前
8秒前
LI发布了新的文献求助10
9秒前
科研通AI2S的应助被cc采纳,获得10
9秒前
Eric完成签到,获得积分10
9秒前
9秒前
桐桐的应助被tulipqq采纳,获得10
9秒前
9秒前
9秒前
科研通AI6.4的应助被香香香采纳,获得10
9秒前
10秒前
11秒前
无极微光的应助被熬夜的小王采纳,获得20
11秒前
11秒前
李刚发布了新的文献求助10
12秒前
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952